Skip to Content

Vectibix Approval History

FDA Approved: Yes (First approved September 27, 2006)
Brand name: Vectibix
Generic name: panitumumab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Colorectal Cancer

Vectibix (panitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer.

Development History and FDA Approval Process for Vectibix

DateArticle
Jun 29, 2017Approval FDA Approves Vectibix (panitumumab) for Use in Wild-Type RAS Metastatic Colorectal Cancer
May 23, 2014Approval FDA Approves First-Line Use of Vectibix (panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer
Sep 27, 2006Approval FDA Approves Vectibix (panitumumab) to Treat Patients with Metastatic Colorectal Cancer
Mar 30, 2006Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide